CLINICAL TRIALS PROFILE FOR COPPER CU-64 DOTATATE

All Clinical Trials for copper cu-64 dotatate

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT04234568 ↗	Testing the Addition of an Anti-cancer Drug, Triapine, to the Usual Radiation-Based Treatment (Lutetium Lu 177 Dotatate) for Neuroendocrine Tumors	Recruiting	National Cancer Institute (NCI)	Phase 1	2020-06-29	This phase I trial studies the side effects and best dose of triapine when given together with lutetium Lu 177 dotatate in treating patients with neuroendocrine tumors. Triapine may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Radioactive drugs, such as lutetium Lu 177 dotatate, may carry radiation directly to tumor cells and not harm normal cells. Giving triapine and lutetium Lu 177 dotatate together may be a good way in treating patients with neuroendocrine tumors.
NCT06016855 ↗	Surgical Debulking Prior to Peptide Receptor Radionuclide Therapy in Well Differentiated Gastroenteropancreatic Neuroendocrine Tumors	RECRUITING	Vanderbilt-Ingram Cancer Center	PHASE4	2024-05-31	This phase IV trial evaluates how well giving standard of care (SOC) peptide receptor radionuclide therapy (PRRT) after SOC surgical removal of as much tumor as possible (debulking surgery) works in treating patients with grade 1 or 2, somatostatin receptor (SSTR) positive, gastroenteropancreatic neuroendocrine tumors (GEP-NETs) that have spread from where they first started (primary site) to the liver (hepatic metastasis). Lutetium Lu 177 dotatate is a radioactive drug that uses targeted radiation to kill tumor cells. Lutetium Lu 177 dotatate includes a radioactive form (an isotope) of the element called lutetium. This radioactive isotope (Lu-177) is attached to a molecule called dotatate. On the surface of GEP-NET tumor cells, a receptor called a somatostatin receptor binds to dotatate. When this binding occurs, the lutetium Lu 177 dotatate drug then enters somatostatin receptor-positive tumor cells, and radiation emitted by Lu-177 helps kill the cells. Giving lutetium Lu 177 dotatate after surgical debulking may better treat patients with grade 1/2 GEP-NETs
NCT06455358 ↗	61Cu-NODAGA-LM3 PET/CT for the Detection of Neuroendocrine Tumors (COPPER PET in NET)	RECRUITING	University Hospital, Basel, Switzerland	PHASE1	2025-02-05	The goal of this monocentric, open-label, randomized-controlled, reader-blind clinical study is to assess the safety of the radiolabeled somatostatin receptor ligand, 61Cu-NODAGA-LM3, and its sensitivity in comparison to the standard of care, 68Ga-DOTATOC, for PET/CT imaging in patients with well differentiated bronchopulmonary and gastroenteropancreatic neuroendocrine tumors.

Clinical Trial Conditions for copper cu-64 dotatate

Condition Name

Condition Name for copper cu-64 dotatate
Intervention	Trials
Digestive System Neuroendocrine Tumor	1
Digestive System Neuroendocrine Tumor G1	1
Digestive System Neuroendocrine Tumor G2	1
Metastatic Digestive System Neuroendocrine Neoplasm	1

Condition MeSH

Condition MeSH for copper cu-64 dotatate
Intervention	Trials
Neuroendocrine Tumors	2

Clinical Trial Locations for copper cu-64 dotatate

Trials by Country

Trials by Country for copper cu-64 dotatate
Location	Trials
United States	11
Switzerland	1

Trials by US State

Trials by US State for copper cu-64 dotatate
Location	Trials
California	1
Arizona	1
Tennessee	1
Utah	1
Pennsylvania	1

Clinical Trial Progress for copper cu-64 dotatate

Clinical Trial Phase

Clinical Trial Phase for copper cu-64 dotatate
Clinical Trial Phase	Trials
PHASE4	1
PHASE1	1
Phase 1	1

Clinical Trial Status

Clinical Trial Status for copper cu-64 dotatate
Clinical Trial Phase	Trials
RECRUITING	3

Clinical Trial Sponsors for copper cu-64 dotatate

Sponsor Name

Sponsor Name for copper cu-64 dotatate
Sponsor	Trials
National Cancer Institute (NCI)	1
Vanderbilt-Ingram Cancer Center	1
University Hospital, Basel, Switzerland	1

Sponsor Type

Sponsor Type for copper cu-64 dotatate
Sponsor	Trials
OTHER	2
NIH	1

Clinical Trials Update, Market Analysis, and Projection: COPPER CU-64 DOTATATE

Last updated: May 3, 2026

What is Cu-64 dotatate and where does it sit in the oncology pipeline?

Copper Cu-64 dotatate (commonly written as Cu-64 DOTATATE) is a somatostatin receptor-targeted radiopharmaceutical built on a somatostatin analog carrier (DOTATATE) labeled with Cu-64. The program targets tumors expressing somatostatin receptors, with the dominant clinical focus in neuroendocrine tumors (NETs) and related receptor-positive malignancies.

Two characteristics shape both clinical positioning and commercial expectations:

• Imaging-dominant intent in early use-cases (quantitative biodistribution and lesion detection), with downstream development toward theranostic alignment with peptide receptor radionuclide therapy (PRRT) standards.
• A development path that overlaps with the established Ga-68/ Lu-177 PRRT workflow, creating both competitive substitution risk and potential workflow expansion.

What is the latest clinical development status?

Sufficient information is not available in the provided prompt to produce a complete and accurate, trial-by-trial “clinical trials update” with dates, phases, enrollment counts, and outcomes.

What is the market context for somatostatin receptor radiopharmaceuticals?

Core market segments

Commercial demand for somatostatin receptor imaging and PRRT clusters into four practical buying centers:

1. NET diagnostic imaging (patient selection, staging, and disease mapping)
2. Treatment response assessment (baseline vs follow-up comparison)
3. Theranostic pathway enablement (selecting candidates for PRRT)
4. Retreatment and line-of-therapy management (repeat imaging and ongoing surveillance)

Why this segment is spend-at-scale

The installed base is supported by:

• Chronic disease management cycles in NETs
• Repeated imaging and response monitoring
• Long-term PRRT planning where imaging findings influence treatment eligibility

Key commercial dynamics

Cu-64 DOTATATE competes on:

• Diagnostic performance (lesion detection sensitivity and specificity)
• Operational fit (site logistics, labeling capacity, radiochemistry workflow)
• Regulatory label scope (indication breadth drives addressable patient volume)
• Payer reimbursement and imaging reimbursement structures
• Theranostic compatibility with downstream PRRT practices

How does Cu-64 DOTATATE compare with the current standard of care?

Standard-of-care imaging

In somatostatin receptor imaging, widely used tracers include Ga-68 DOTATATE PET. PRRT commonly uses Lu-177 DOTATATE.

Cu-64 DOTATATE’s commercial thesis typically rests on:

• Imaging sensitivity and lesion detectability
• Quantification utility for selecting and sequencing treatment
• Potential workflow advantages versus existing PET tracers depending on supply chain and on-site infrastructure

Substitution risk

Substitution risk is high if:

• Clinical adoption does not translate into materially improved detection vs Ga-68 DOTATATE
• Sites do not have the capability or cost structure to adopt Cu-64 PET imaging

Theranostic upside

Theranostic upside is strongest if:

• Quantitative readouts improve PRRT selection and reduce “screen-fail” rates
• Imaging changes reduce time-to-treatment or improve continuity of care

What does this imply for addressable market size?

A reliable market projection requires:

• Approved indication(s) and label language
• Country-by-country prevalence and eligible patient numbers
• Trial-to-approval timelines
• Uptake curves by site type (academic vs community)
• Dose frequency assumptions tied to imaging schedules

None of those required inputs are contained in the prompt.

What is a defensible market projection framework for Cu-64 DOTATATE?

Even without trial details, a projection framework for radiopharmaceutical imaging can be structured around four variables:

1. Eligible patient population
   • NET prevalence and receptor positivity rate
   • Imaging utilization rate per patient per year
2. Market share capture
   • Share of PET imaging performed using Cu-64 DOTATATE
   • Competitive switching from Ga-68 DOTATATE
3. Reimbursement coverage
   • National reimbursement policy acceptance and average reimbursement per study
4. Site capacity constraints
   • Fraction of sites able to produce or receive the tracer with acceptable turnaround time

A complete numeric projection cannot be generated without the missing approval and commercial inputs.

Clinical trial readouts: what to look for in the next catalysts

For radiopharmaceutical development, the decisive datapoints investors and buyers track are:

• Sensitivity and specificity relative to comparator imaging standard
• Lesion-based metrics (overall lesion count detected, per-patient detection rate)
• Quantitative accuracy (SUV or other quantification reliability metrics)
• Safety profile (largely infusion-level adverse event patterns in imaging cohorts)
• Practicality endpoints (manufacturing yield, timing from synthesis to administration)

A “latest update” with these endpoints requires specific trial publications and registry results.

Key Takeaways

• Cu-64 DOTATATE is a somatostatin receptor-targeted radiopharmaceutical positioned in the NET imaging and potential theranostic pathway.
• Market demand exists due to chronic NET care cycles and repeated imaging needs tied to PRRT decisioning.
• A complete clinical trials update and numeric market projection are not possible from the provided prompt because the necessary trial, regulatory, and commercial inputs are not present.

FAQs

1. Is Cu-64 DOTATATE an imaging or therapeutic radiopharmaceutical?
   Cu-64 DOTATATE is developed as an imaging radiopharmaceutical (PET) in somatostatin receptor-positive oncology.

2. Which patient population does Cu-64 DOTATATE target?
   The primary clinical focus is neuroendocrine tumors and other somatostatin receptor-expressing malignancies.

3. What does Cu-64 DOTATATE compete against commercially?
   It competes mainly with Ga-68 DOTATATE PET imaging workflows and broader NET imaging practices that influence downstream PRRT use.

4. What drives market adoption for this tracer?
   Diagnostic performance, workflow compatibility, regulatory label scope, reimbursement coverage, and site delivery logistics.

5. What are the near-term catalysts for the program?
   The most important catalysts are trial readouts demonstrating imaging performance against standards and any resultant regulatory milestones.

References

[1] (No sources provided in the prompt to cite.)